These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19996046)

  • 1. Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: analyses of the reaching for excellence in adolescent care and health (REACH) project.
    Ding H; Wilson CM; Modjarrad K; McGwin G; Tang J; Vermund SH
    Arch Pediatr Adolesc Med; 2009 Dec; 163(12):1100-5. PubMed ID: 19996046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
    Flynn PM; Rudy BJ; Douglas SD; Lathey J; Spector SA; Martinez J; Silio M; Belzer M; Friedman L; D'Angelo L; McNamara J; Hodge J; Hughes MD; Lindsey JC;
    J Infect Dis; 2004 Jul; 190(2):271-9. PubMed ID: 15216461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.
    Rutstein RM; Gebo KA; Flynn PM; Fleishman JA; Sharp VL; Siberry GK; Spector SA
    Med Care; 2005 Sep; 43(9 Suppl):III15-22. PubMed ID: 16116305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.
    Pence BW; Miller WC; Gaynes BN; Eron JJ
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):159-66. PubMed ID: 17146374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic.
    McNabb J; Ross JW; Abriola K; Turley C; Nightingale CH; Nicolau DP
    Clin Infect Dis; 2001 Sep; 33(5):700-5. PubMed ID: 11486292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
    Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A
    AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents.
    Murphy DA; Sarr M; Durako SJ; Moscicki AB; Wilson CM; Muenz LR;
    Arch Pediatr Adolesc Med; 2003 Mar; 157(3):249-55. PubMed ID: 12622674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort.
    Rudy BJ; Lindsey JC; Flynn PM; Bosch RJ; Wilson CM; Hughes ME; Douglas SD;
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):213-21. PubMed ID: 16545007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.
    Murphy DA; Belzer M; Durako SJ; Sarr M; Wilson CM; Muenz LR;
    Arch Pediatr Adolesc Med; 2005 Aug; 159(8):764-70. PubMed ID: 16061785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Ylitalo N; Brogly S; Hughes MD; Nachman S; Dankner W; Van Dyke R; Seage GR;
    Arch Pediatr Adolesc Med; 2006 Aug; 160(8):778-87. PubMed ID: 16894075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
    Geretti AM; Harrison L; Green H; Sabin C; Hill T; Fearnhill E; Pillay D; Dunn D;
    Clin Infect Dis; 2009 May; 48(9):1296-305. PubMed ID: 19331585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
    Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
    Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil.
    Tuboi SH; Harrison LH; Sprinz E; Albernaz RK; Schechter M
    J Acquir Immune Defic Syndr; 2005 Nov; 40(3):324-8. PubMed ID: 16249707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
    Sterling TR; Chaisson RE; Keruly J; Moore RD
    J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of early highly active antiretroviral therapy on viral suppression among newly diagnosed men who have sex with men living with human immunodeficiency virus in Xi'an, China.
    Wei X; Zhang Y; Santella AJ; Wang L; Zhuang G; Li S; Zhang H
    J Med Virol; 2019 Jul; 91(7):1263-1271. PubMed ID: 30840771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review.
    Hart JE; Jeon CY; Ivers LC; Behforouz HL; Caldas A; Drobac PC; Shin SS
    J Acquir Immune Defic Syndr; 2010 Jun; 54(2):167-79. PubMed ID: 20375848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.